



Artificial Intelligence (AI) Tools: If You Are Using AI to Support Your Drafting of Letters of Medical Necessity for DYSPORT, Consider Including the Following Prompts:

Using an AI model with appropriate prompts may improve the quality of the output. You may want to consider including the following information when working with an AI model.

Potential AI Prompt for a Letter of Medical Necessity: Cervical Dystonia

Write a Letter of Medical Necessity for the use of Dysport® (abobotulinumtoxinA) for a patient with cervical dystonia in response to a denial from a health insurance payer. The letter should be medically sound, patient-specific, and supported by clinical evidence and national guidelines. Use precise, professional language, appropriate for physician correspondence and cite appropriate references. Limit to 1 page and use the following section structure: header, introduction, treatment rationale, evidence and guidelines, and conclusion.

Please ensure the letter includes the following content and bracket content that needs to be populated per a specific patient and show the content in bold text:

- **Patient details:** Diagnosis (cervical dystonia), severity (TWSTRS total score and subscale scores for severity disability, and VAS score for pain), prior therapy use (if possible, note clinical response), response and duration to previous treatment with DYSPORT, and any other clinically relevant impact
- **Treatment requested:** Dysport (abobotulinumtoxinA)
- **Evidence support:** Reference the efficacy and safety results of DYSPORT as evaluated in key (pivotal) clinical trials that informed prescribing information for the cervical dystonia indication. Use data and statistics in the draft letter
- **Guideline support:** Note any relevant guidelines and current consensus statements on the treatment of cervical dystonia
- **Justification:** Why other treatments are not appropriate for this patient
- **Conclusion:** Request expedited approval and advocate for the initiation or continuation of DYSPORT access based on evidence provided

TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; VAS, Visual Analogue Scale.

The information provided above is for information purposes only and includes general guidance related to use of AI tools in drafting letters of medical necessity. Use of this information does not guarantee that a health plan will provide coverage or reimbursement for DYSPORT and is not intended to be a substitute for or an influence on your independent medical judgment. It is the end user's responsibility to confirm the accuracy and appropriateness of any input to or output of any AI tool.

INDICATIONS

DYSPORT (abobotulinumtoxinA) for injection is indicated for the treatment of:

- spasticity in patients 2 years of age and older
- cervical dystonia in adults

Important Safety Information

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of DYSPORT and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including **BOXED WARNING** and [Medication Guide](#).

Potential AI Prompt for a Letter of Medical Necessity: Adult Spasticity

Write a Letter of Medical Necessity for the use of Dysport® (abobotulinumtoxinA) for a patient with adult spasticity in response to a denial from a health insurance payer. The letter should be medically sound, patient-specific, and supported by clinical evidence and national guidelines. Use precise, professional language, appropriate for physician correspondence and cite appropriate references. Limit to 1 page and use the following section structure: header, introduction, treatment rationale, evidence and guidelines, and conclusion.

Please ensure the letter includes the following content and bracket content that needs to be populated per a specific patient and show the content in bold text:

- **Patient details:** Diagnosis (adult spasticity), severity (MAS score), prior therapy use (if possible, note clinical response), response and duration to previous treatment with DYSPORT, and any other clinically relevant impact
- **Treatment requested:** Dysport (abobotulinumtoxinA)
- **Evidence support:** Reference the efficacy and safety results of DYSPORT as evaluated in key (pivotal) clinical trials that informed prescribing information for the adult spasticity indication. Use data and statistics in the draft letter
- **Guideline support:** Note any other relevant guidelines and current consensus statements on the treatment of spasticity in adult patients
- **Justification:** Why other treatments are not appropriate for this patient
- **Conclusion:** Request expedited approval and advocate for the initiation or continuation of DYSPORT access based on evidence provided

MAS, Modified Ashworth Scale.

The information provided above is for information purposes only and includes general guidance related to use of AI tools in drafting letters of medical necessity. Use of this information does not guarantee that a health plan will provide coverage or reimbursement for DYSPORT and is not intended to be a substitute for or an influence on your independent medical judgment. It is the end user's responsibility to confirm the accuracy and appropriateness of any input to or output of any AI tool.

IMPORTANT SAFETY INFORMATION (continued)

Contraindications

DYSPORT is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow's milk protein, or to any of the components in the formulation, or infection at the proposed injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a serious reaction occurs, discontinue DYSPORT and institute appropriate medical therapy immediately. Warnings and Precautions

Warnings and Precautions

Lack of Interchangeability Between Botulinum Toxin Products

The potency Units of DYSPORT are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Potential AI Prompt for a Letter of Medical Necessity: Pediatric Spasticity

Write a Letter of Medical Necessity for the use of Dysport® (abobotulinumtoxinA) for a patient with pediatric spasticity in response to a denial from a health insurance payer. The letter should be medically sound, patient-specific, and supported by clinical evidence and national guidelines. Use precise, professional language, appropriate for physician correspondence and cite appropriate references. Limit to 1 page and use the following section structure: header, introduction, treatment rationale, evidence and guidelines, and conclusion.

Please ensure the letter includes the following content and bracket content that needs to be populated per a specific patient and show the content in bold text:

- **Patient details:** Diagnosis (pediatric spasticity), severity (MAS score), prior therapy use (if possible, note clinical response), response and duration to previous treatment with DYSPORT, and any other clinically relevant impact
- **Treatment requested:** Dysport (abobotulinumtoxinA)
- **Evidence support:** Reference the efficacy and safety results of DYSPORT as evaluated in key (pivotal) clinical trials that informed prescribing information for the pediatric spasticity indication. Use data and statistics in the draft letter
- **Guideline support:** Note any other relevant guidelines and current consensus statements on the treatment of spasticity in pediatric patients
- **Justification:** Why other treatments are not appropriate for this patient
- **Conclusion:** Request expedited approval and advocate for the initiation or continuation of DYSPORT access based on evidence provided

MAS, Modified Ashworth Scale.

The information provided above is for information purposes only and includes general guidance related to use of AI tools in drafting letters of medical necessity. Use of this information does not guarantee that a health plan will provide coverage or reimbursement for DYSPORT and is not intended to be a substitute for or an influence on your independent medical judgment. It is the end user's responsibility to confirm the accuracy and appropriateness of any input to or output of any AI tool.

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions (continued)

Dysphagia and Breathing Difficulties

Treatment with DYSPORT and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Treatment of cervical dystonia with botulinum toxins may weaken accessory muscles of ventilation, which may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these muscles. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT.

Please see additional Important Safety Information throughout and full Prescribing Information, including **BOXED WARNING and Medication Guide.**

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions (continued)

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, vCJD, or CJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Intradermal Immune Reaction

The possibility of an immune reaction when injected intradermally is unknown. The safety of DYSPORT for the treatment of hyperhidrosis has not been established. DYSPORT is approved only for intramuscular injection.

Pre-existing Conditions at the Injection Site

Caution should be exercised when DYSPORT is used where the targeted muscle shows excessive weakness or atrophy.

Adverse Reactions

- The most common adverse reactions ($\geq 4\%$) in adults with upper limb spasticity include muscular weakness; in adults with lower limb spasticity ($\geq 5\%$) include falls, muscular weakness, and pain in extremity
- The most common adverse reactions ($\geq 10\%$) in pediatric patients with upper limb spasticity include upper respiratory tract infection and pharyngitis; in pediatric patients with lower limb spasticity include nasopharyngitis, cough, and pyrexia
- The most common adverse reactions ($\geq 5\%$) in adults with cervical dystonia include muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders

Drug Interactions

Co-administration of DYSPORT and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should only be performed with caution because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of DYSPORT may potentiate systemic anticholinergic effects such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before and after administration of DYSPORT.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Ipsen at 1-855-463-5127.

You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, Including BOXED WARNING and Medication Guide.